SHORT ANSWER
No. FDA decides whether a product is a drug from its intended use, and intended use is read from the whole presentation: product names, descriptions, imagery, bundled supplies, testimonials, and social posts. In its peptide warning letters FDA states that it read the research-use-only wording and set it aside because the rest of the site pointed to human use.
This material is general educational information as of the “last reviewed” date. It is not legal advice and may not reflect later developments or facts specific to your business. Links are provided so readers can inspect the primary or official sources.
01 / WHAT FDA SAYS
The letters address the disclaimer directly
FDA's peptide warning letters do not ignore research-use-only labeling. They quote it, and then explain why it does not control. The March 2026 letter to Gram Peptides puts it in one sentence:
“Despite statements on your product labeling marketing your products for ‘research use only’ and ‘not for human consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”
The February 2025 letter to USApeptide.com lists the site's own boundary language, “research use only,” “not for human consumption,” “lab purposes only,” and “not intended to diagnose, cure, mitigate, treat or prevent disease,” before reaching the same conclusion. The December 2024 letter to Xcel Research follows the same structure.
A warning letter describes what FDA observed on one site on one date. It is not a statute, a rule for every seller, or a prediction about any other storefront.
02 / THE MECHANISM
Intended use is read from objective intent, not from the label
Under 21 U.S.C. § 321(g)(1), whether a product is a drug turns on what it is intended to be used for. The regulation that explains how intent is shown, 21 CFR § 201.128, points to the “objective intent of the persons legally responsible,” as established by labeling, advertising, oral or written statements, and the circumstances of distribution.
A disclaimer is one written statement among many. When the surrounding material describes appetite suppression, glucose control, fat loss, muscle repair, or brand equivalence to an approved drug, the objective intent FDA reads is a human therapeutic one. The disclaimer does not subtract those statements; it sits beside them.
03 / WHERE FDA LOOKS
The product page is not the only evidence
RUO Clear compiled the 185 FDA warning letters issued to peptide, GLP-1, and research-chemical sellers between 2021 and July 2026. Across that set, FDA cited evidence from well beyond the product listing:
- Product pages and descriptions (19 letters)
- Bacteriostatic water, syringes, or needles bundled or sold alongside (15 letters)
- Facebook posts (12), Instagram posts (8), and YouTube videos (4) attributed to the seller
- Blog or educational articles on the seller's own site (8 letters)
- Customer reviews and testimonials quoted as efficacy evidence (7 letters)
- Website metatags and search keywords cited as proof of intended use (2 letters)
- The research-use-only or not-for-human-consumption disclaimer expressly set aside (15 letters)
The figures reflect how the letters were tagged during compilation. They are offered to show the range of evidence FDA has used, not as a statistic about enforcement odds.
04 / WHAT GOT QUOTED
The phrases FDA lifted from the sites
The letters reproduce the seller's own copy. The patterns repeat across all three examples cited here.
- Outcome language: “demonstrated significant potential for reducing body weight, improving glucose handling, and enhancing lipid metabolism” (Gram Peptides).
- Brand equivalence: “Semaglutide, also marketed under the brand names Ozempic, Rybelsus and Wegovy, is an FDA-approved injectable for weight loss” (USApeptide.com).
- Clinical framing aimed at people: “helps test subjects maintain stable blood glucose levels” and “cardiovascular protection” (Xcel Research).
- Administration context: “Bacteriostatic Water for Injection” and “10 pack of insulin syringes” listed beside the peptides (Gram Peptides, USApeptide.com).
05 / THE FTC ANGLE
Net impression, and what a disclosure can and cannot fix
The FTC evaluates express and implied claims by the overall net impression an advertisement leaves, including names and images. Its Health Products Compliance Guidance explains that a qualifying disclosure must be clear and conspicuous, and that no disclosure can cure a claim it directly contradicts.
Applied to a peptide storefront: a footer that says the products are not for human use does not change the impression left by a product named for fat loss, a testimonial about recovery, or an image of an injection.
06 / WHAT TO REVIEW
Review the storefront the way the letters read it
Because intent is read from the whole presentation, the review has to cover the whole presentation. Work through each surface FDA has cited, and record what was found and what was changed.
- Product names, slugs, and collection names that name an outcome or an approved brand
- Descriptions that describe effects in people or “test subjects”
- Bundles, kits, and cross-sells that supply a route of administration
- Testimonials, reviews, and before-and-after imagery anywhere on the domain
- Blog posts, guides, and social accounts the storefront links to or is attributed
- Page titles, metatags, and search keywords
- Where the disclaimer sits relative to the claims it is meant to qualify
QUESTIONS
Related questions
Does removing the disclaimer make things better?
No. The disclaimer is not the problem; the surrounding claims are. Keep accurate boundary language, and fix the names, descriptions, bundles, and testimonials that contradict it.
Does a clean product page protect a site with older blog posts?
Not on its own. FDA has cited blog articles, social posts, and customer reviews attributed to the seller. Older content on the same domain or linked accounts is part of the presentation.
Can RUO Clear tell me whether my site is compliant?
No. A scan reports what was observed, which source each finding maps to, and what was not examined. It is issue-spotting and education, not a legal determination, a certification, or a prediction of what a regulator or processor will do.
SOURCES
Sources cited
Each source is listed with its class so government authority, agency guidance, enforcement examples, and private policy are never blended into one rule.
Quotes the research-use-only labeling and states that website evidence establishes intended human use.
Lists four separate boundary statements from the site before setting them aside; cites brand-equivalence and dosing claims.
Cites outcome and cardiovascular claims framed around “test subjects” despite research-use wording.
Objective intent shown by labeling, advertising, written statements, and circumstances of distribution.
A product is a drug based on the use it is intended for.
Net impression, clear and conspicuous disclosures, and why a disclosure cannot cure a contradictory claim.